Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DXR vs INFU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INFU Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)

INFU Overall Winner 6-Pillar Tally: DXR 1 – 5 INFU Matrix Metrics: DXR 5 – 5 INFU

As of Nov 16, 2026, InfuSystem Holdings, Inc. (INFU) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DXR carries a Unified Composite Score of 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin), whereas INFU carries 36.6/100 (SELL) at $14.79 (26.4x Forward P/E, 8.5% operating margin).

  • Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. INFU 36.6/100 SELL), INFU captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (8.5% vs. -5894.3% operating margin) and revenue trajectory (+3.0% vs. +25.5% YoY).
  • Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile INFU trades in a Markup technical trend (CONSOLIDATION options phase, RSI 59.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXR vs INFU
DXR NASDAQ
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07
INFU NYSE American Head-to-Head Winner
InfuSystem Holdings, Inc.
Surgical & Medical Instruments & Apparatus
$14.79
+0.48% 1D
Market Cap $294.9M
TTM Revenue $144M
Forward P/E 26.4x
Beta / 30D Vol 0.78β · 48% Vol
Unified Composite Score
36.6 / 100 SELL
Tech 8.0 Fund 28.0 Flow 54.0 Mom 25.9
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 59.9 · SMA20: $14.18 · SMA50: $13.44

6-Pillar Scorecard Institutional Category Breakdown (DXR 1 – 5 INFU)

Columns: Metric · DXR · INFU
1. Valuation Multiples INFU
Forward P/E 64.5x 26.4x
Trailing P/E 7.7x 33.5x
PEG Ratio N/M 1.73x
EV / Revenue N/M 2.1x
2. Growth & Scale DXR
Revenue Growth (YoY) +25.5% +3.0%
Earnings Growth (YoY) +329.3% +36.4%
TTM Revenue (USD) $31,360 $144M
Market Cap $49.5M $294.9M
3. Profitability & Quality INFU
Gross Margin 100.0% 57.6%
Operating Margin -5894.3% 8.5%
Net Profit Margin 19861.4% 6.5%
Return on Equity (ROE) 14.2% 15.8%
4. Balance Sheet & Cash Flow INFU
Cash Generation (TTM) N/A $13M
Cash Flow Margin N/A 9.2%
Net Cash / Leverage $8.88 Book/Sh · 14.2% ROE $13M Net Debt (0.35x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning INFU
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 47.0% (7th %ile)
Put/Call OI Skew N/A 2.74x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat INFU
OpEx & R&D Intensity N/A 49.1% of Rev ($71M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXR (5) vs INFU (5)
Institutional Metric DXR INFU Criterion Row Edge
Market Capitalization
Scale
$49.5M $294.9M Larger Scale INFU
Trailing P/E Ratio
Valuation
7.7x 33.5x Lower Multiple DXR
Forward P/E Ratio
Valuation
64.5x 26.4x Lower Multiple INFU
Revenue Growth (YoY)
Growth
+25.5% +3.0% Higher Growth DXR
Operating Margin (TTM)
Profitability
-5894.3% 8.5% Higher Margin INFU
Net Profit Margin
Profitability
19861.4% 6.5% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
14.2% 15.8% Higher ROE INFU
52-Week Range Position
Momentum
2% ($8–$15) 92% ($7–$15) Stronger Trend INFU
Beta / 30D Volatility
Risk Regime
0.28β · 32% Vol 0.78β · 48% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 36.6 / 100 (SELL) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$31,360 $144M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 57.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.73x PEG · 2.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.88 Book/Sh · 14.2% ROE) $13M ($13M Net Debt (0.35x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INFU +27.24 pp
DXR: -16.87% · INFU: +10.37%
3M Horizon INFU +38.17 pp
DXR: -19.66% · INFU: +18.51%
6M Horizon INFU +59.79 pp
DXR: -17.44% · INFU: +42.35%
1Y Horizon INFU +78.84 pp
DXR: -33.27% · INFU: +45.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DXR vs INFU. Trailing 12-month operating profitability (DXR -5894.3% vs INFU 8.5%) and valuation multiples (DXR 64.5x vs INFU 26.4x Forward P/E) are benchmarked directly in Pillar 4 below.

DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x
INFU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$144M
Gross Margin57.6%
Op. Margin8.5%
ROE / Fwd P/E15.8% · 26.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INFU CONSOLIDATION
22d in phase · OBV ACCUMULATION
Current IV 47.0%
IV Percentile 7th %ile
Put/Call OI Skew 2.74x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact INFU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INFU Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $294.9M market capitalization and 8.5% operating margin.
OpEx & R&D Reinvestment 49.1% of Rev ($71M)
90D Engineering Disclosures 0 Published

Investor FAQ DXR vs INFU Key Questions & Quantitative Answers

As of Nov 16, 2026, InfuSystem Holdings, Inc. (INFU) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DXR carries a Unified Composite Score of 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin), whereas INFU carries 36.6/100 (SELL) at $14.79 (26.4x Forward P/E, 8.5% operating margin). Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. INFU 36.6/100 SELL), INFU captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (8.5% vs. -5894.3% operating margin) and revenue trajectory (+3.0% vs. +25.5% YoY). Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile INFU trades in a Markup technical trend (CONSOLIDATION options phase, RSI 59.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXR leads the Growth & Scale pillar: DXR posts +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin), compared with INFU at +3.0% YoY revenue growth and +36.4% YoY earnings growth on $144M TTM revenue (57.6% gross margin, 8.5% operating margin). On trailing 12-month operating scale, DXR generates $31,360 in USD-normalized revenue versus $144M for INFU. In operating R&D and SG&A reinvestment, DXR deploys N/A (0 90-day corporate R&D disclosures) versus 49.1% of Rev ($71M) (0 disclosures) for INFU.

INFU screens cheaper on headline valuation multiples. DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas INFU trades at 26.4x Forward P/E, 33.5x Trailing P/E, 1.73x PEG, and 2.1x EV/Revenue (9.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXR (14.2% ROE) versus INFU (15.8% ROE) capital efficiency.

In options market volatility and institutional positioning, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk). By comparison, INFU carries 47.0% implied volatility (7th %ile, Compressed (<25th %ile)), a 2.74x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.78β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.